

# PROTOCOLS, MEDICATIONS & DEVICES (PMD) STANDING COMMITTEE

## Minutes

November 15, 2012 - 12:00 PM

150 N. 18<sup>th</sup> Ave., Conference Room 540A

- I. Call to Order – Toni Gross, MD, Chair  
Meeting was called to order at 12:01 p.m.
- II. Roll Call – Jennifer Herbert (12 Members, 7 required for quorum)

### Members Present

Toni Gross, MD (Chair)  
Patricia Ellis, RN\*  
Charlie Smith (EMS Liaison)  
Terry Mason (Vice Chair)  
Garth Gemar, MD  
Jason Johnson, M.D.\*  
Bruce Toliver\*

### Members Absent

Rob Jarvis  
Terry Shine, RN  
Steven Curry, MD  
Michael Pfleger, MD (STAB Liaison)  
Sue Kern, RN

\* indicates teleconference

- III. Chairman's Report – Toni Gross, MD
  - a. Membership update: Welcome Jason Johnson, MD
- IV. Bureau Report – Ben Bobrow, MD: Dr. Bobrow had nothing to report.
- V. Discussion and Action Items
  - a. Discuss, amend, and approve PMD minutes of May 24, 2012  
Charlie Smith made a motion to approve the May 24, 2012 minutes as presented and Terence Mason second the motion. **Motion passes and minutes are approved.**
  - b. Select a workgroup to update the Triage, Treatment and Transport Guidelines
  - c. Select a workgroup to propose updates to R9-25-503, Table 1 (drug box)
  - d. Select a workgroup to propose updates to the Drug Profiles. Members decided to form just one workgroup charged with updating the TTTG, R9-25-503 Table1, and Drug Profiles (items b, c and d). Volunteers are as follows: Patricia Ellis, Garth Gemar, Brian Smith, Charlie Smith and Jason Johnson. **Group report to be submitted back to PMD in March, 2013.**
  - e. Consider additional information pertaining to the request to add Cyanokit Administration (hydroxocobalamin, 5 g for intravenous infusion) as an optional agent to R9-25-503, Table 1 – Sean Culliney.
  - f. Discuss, amend, approve the addition of Cyanokit Administration (hydroxocobalamin, 5 g for intravenous infusion) as an optional agent to R9-25-503, Table 1 – Sean Culliney.  
Terence Mason made a motion to add the Cyanokit to the R9-25-503 Table 1 as an optional drug with the caveat that they look at the indications for use and make sure that the drug profile is satisfactory to all. Charlie Smith seconded the motion. Discussion ensued. **Motion passes and is approved.** Jennifer Herbert updated the Table 1 and the drug profile.
  - g. Discuss, amend, approve the addition of Ketamine as an optional agent to R9-25-503, Table 1 drug box – Garth Gemar, MD

Dr. Gemar presented the committee with a draft drug profile. Discussion ensues. Dr Gemar makes a motion to add Ketamine to Table 1 as an optional drug. Discussion ensues. **This item was not approved.**

- h. Discuss, amend approve Ketamine drug profile – Garth Gemar, MD. **No action was made.**
- i. Consider additional information pertaining to the request to add Proparacaine Ophthalmic drops to R9-25-503, Table 1 drug box as an optional agent – Garth Gemar, MD **No addition information was presented.**
- j. Discuss, amend, approve the addition of Proparacaine Ophthalmic drops as an optional agent to R9-25-503, Table 1 drug box – Garth Gemar, MD  
Dr. Gemar makes a motion to table to the March 21, 2012 meeting, Charlie Smith seconds motion. Motion carries. **This item will be tabled to the next meeting on March 21, 2013.**

- VI. Agenda Items for Next Meeting: Workgroup will report back to PMD on March 21, 2012
- VII. Call to the Public. No response from the public.
- VIII. Summary of Current Events
  - a. American College of Surgeon’s (ACS) Trauma System Consultation - November 26-29, 2012.
- IX. Next Meeting: March 21, 2012, 12:00 P.M. at 150 N. 18<sup>th</sup> Avenue, Room 540A.
- X. Adjournment: Meeting adjourned at 12:55 PM.

Meeting minutes approved by PMD on March 21, 2013